Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; also a board member in both the companies.
Patents/Royalties
Author Samuel Abraham is an inventor to several patents of relevance to the beta glucans described in the study.